Jay Feingold

2.2k total citations · 1 hit paper
53 papers, 1.6k citations indexed

About

Jay Feingold is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Jay Feingold has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Molecular Biology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Jay Feingold's work include CAR-T cell therapy research (12 papers), Lymphoma Diagnosis and Treatment (12 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Jay Feingold is often cited by papers focused on CAR-T cell therapy research (12 papers), Lymphoma Diagnosis and Treatment (12 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Jay Feingold collaborates with scholars based in United States, United Kingdom and Italy. Jay Feingold's co-authors include Anna Berkenblit, Andrew Strahs, Janice P. Dutcher, Mehdi Hamadani, John Radford, Paolo F. Caimi, Karin Havenith, Cezary Szczylik, Alexandra Thiele and Gary R. Hudes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Jay Feingold

50 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Feingold United States	19	802	638	502	499	318	53	1.6k
E. Lin United States	20	590 0.7×	518 0.8×	301 0.6×	304 0.6×	270 0.8×	47	1.7k
Kuniyuki Oka Japan	24	629 0.8×	413 0.6×	405 0.8×	332 0.7×	207 0.7×	101	1.8k
Tanya Trippett United States	24	655 0.8×	580 0.9×	263 0.5×	380 0.8×	135 0.4×	79	1.9k
Natália Buza United States	33	1.2k 1.5×	673 1.1×	430 0.9×	355 0.7×	325 1.0×	134	2.9k
Young‐Ha Oh South Korea	25	627 0.8×	614 1.0×	363 0.7×	292 0.6×	210 0.7×	116	1.8k
Geneviève Belleannée France	24	812 1.0×	366 0.6×	317 0.6×	225 0.5×	269 0.8×	79	1.7k
Daniel Ré Germany	22	829 1.0×	366 0.6×	329 0.7×	1.0k 2.0×	210 0.7×	62	1.9k
Peter Vuylsteke Belgium	19	1.1k 1.4×	439 0.7×	411 0.8×	115 0.2×	383 1.2×	101	1.7k
W. P. Peters United States	22	1.1k 1.3×	315 0.5×	254 0.5×	208 0.4×	521 1.6×	59	1.9k
Yukishige Yamada Japan	19	1.2k 1.5×	857 1.3×	652 1.3×	262 0.5×	279 0.9×	46	2.3k

Countries citing papers authored by Jay Feingold

Since Specialization

Citations

This map shows the geographic impact of Jay Feingold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Feingold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Feingold more than expected).

Fields of papers citing papers by Jay Feingold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Feingold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Feingold. The network helps show where Jay Feingold may publish in the future.

Co-authorship network of co-authors of Jay Feingold

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Feingold. A scholar is included among the top collaborators of Jay Feingold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Feingold. Jay Feingold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamadani, Mehdi, Graham P. Collins, Paolo F. Caimi, et al.. (2021). Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. The Lancet Haematology. 8(6). e433–e445. 63 indexed citations

Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 22(6). 790–800. 264 indexed citations breakdown →

Herrera, Alex F., Carmelo Carlo‐Stella, Graham P. Collins, et al.. (2020). Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 136(Supplement 1). 21–23. 14 indexed citations

Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations

Goldberg, Aaron D., Ehab Atallah, David A. Rizzieri, et al.. (2020). Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research. 95. 106385–106385. 27 indexed citations

Kahl, Brad S., Mehdi Hamadani, John Radford, et al.. (2019). A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 25(23). 6986–6994. 77 indexed citations

Collins, Graham P., Steven M. Horwitz, Andrew Davies, et al.. (2018). Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma. Blood. 132(Supplement 1). 1658–1658. 17 indexed citations

Hamadani, Mehdi, Graham P. Collins, Felipe Samaniego, et al.. (2018). Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 132(Supplement 1). 928–928. 35 indexed citations

Kahl, Brad S., Mehdi Hamadani, Paolo F. Caimi, et al.. (2017). Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma. Blood. 130. 187–187. 6 indexed citations

10.

Figlin, Robert A., Paul de Souza, David F. McDermott, et al.. (2009). Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α. Cancer. 115(16). 3651–3660. 67 indexed citations

11.

Hudes, Gary R., Anna Berkenblit, Jay Feingold, et al.. (2009). Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma. Seminars in Oncology. 36. S26–S36. 44 indexed citations

12.

Dutcher, Janice P., Paul de Souza, David F. McDermott, et al.. (2009). Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology. 26(2). 202–209. 194 indexed citations

13.

Bellmunt, Joaquim, Cezary Szczylik, Jay Feingold, Andrew Strahs, & Anna Berkenblit. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology. 19(8). 1387–1392. 129 indexed citations

14.

Dorsky, David I., et al.. (2001). Efficacy of Clarithromycin in Preventing Viridans Streptococcal Bacteremia following autologous Stem Cell Transplantation. Infection. 29(4). 201–204. 2 indexed citations

15.

Tutschka, P. J., et al.. (2001). Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide and Cyclophosphamide for Patients with Advanced Lymphoma. Acta Haematologica. 105(4). 222–232. 1 indexed citations

16.

Medeiros, Bruno C., William N. Rezuke, Andrew Ricci, et al.. (2000). Kaposi’s Sarcoma following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Acta Haematologica. 104(2-3). 115–118. 25 indexed citations

17.

Bilgrami, S, Nitya G. Chakraborty, Amir Khan, et al.. (1999). Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. Bone Marrow Transplantation. 23(5). 469–474. 38 indexed citations

18.

Dorsky, David I., J S Remington, Richard L. Edwards, et al.. (1997). Ocular Toxoplasmosis After Autologous Peripheral‐Blood Stem‐Cell Transplantation. Clinical Infectious Diseases. 25(5). 1255–1256. 6 indexed citations

19.

Lang, Zhihui & Jay Feingold. (1996). An autonomously replicating eukaryotic expression vector with a tetracycline-responsive promoter. Gene. 168(2). 169–171. 12 indexed citations

20.

Feingold, N, Jay Feingold, & J Dausset. (1969). [Calculation of the desirable number of waiting future recipients of organ transplants].. PubMed. 14(6). 607–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact